Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child

Published byJulie Franklin Modified over 5 years ago

Similar presentations

Presentation on theme: "Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child"— Presentation transcript:

1 Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Lupe Orostegui  Journal of Hepatology  Volume 58, Issue 1, Pages (January 2013) DOI: /j.jhep Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

2 Fig. 1 Time profile of liver function tests after introduction and withdrawal of fondaparinux. AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyltranspeptidase. Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Download ppt "Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child"

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages 179-202 (January 2016) DOI: 10.1016/j.jhep.2015.07.040.

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)

Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)

Volume 46, Issue 3, Pages (March 2007)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 

Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases

Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)

Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?

MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)

Volume 51, Issue 6, Pages (December 2009)
Reactive oxygen species in the normal and acutely injured liver

Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 

Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C

NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis

Immigration and viral hepatitis
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.
Volume 66, Issue 1, Pages 1-4 (January 2017)

Volume 66, Issue 1, Pages 1-4 (January 2017)
Living donor liver transplantation: is the hype over?

Living donor liver transplantation: is the hype over?
Clinical Approach to the Patient With Abnormal Liver Test Results

Clinical Approach to the Patient With Abnormal Liver Test Results

Similar presentations

Ads by Google